Cargando…

Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data

BACKGROUND: Acute myocardial infarction (AMI), a major source of morbidity and mortality, is also associated with excess costs. Findings from previous studies were divergent regarding the effect on health care expenditure of adherence to guideline-recommended medication. However, gender-specific med...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirsch, Florian, Becker, Christian, Kurz, Christoph, Schwettmann, Lars, Schramm, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751107/ https://www.ncbi.nlm.nih.gov/pubmed/33342431 http://dx.doi.org/10.1186/s12913-020-05946-4

Ejemplares similares

Patients with coronary artery disease after acute myocardial infarction: effects of continuous enrollment in a structured Disease Management Program on adherence to guideline-recommended medication, health care expenditures, and survival
por: Kirsch, Florian, et al.
Publicado: (2020)

The relationship between body mass index and health-related quality of life in COPD: real-world evidence based on claims and survey data
por: Huber, Manuel B., et al.
Publicado: (2020)

In-hospital myocardial infarction and adherence to evidence-based drug therapies: a real-world evaluation
por: Soldati, Salvatore, et al.
Publicado: (2021)

Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018
por: Lõiveke, Piret, et al.
Publicado: (2021)

Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction
por: Solomon, Matthew D., et al.
Publicado: (2020)

Long-term secondary prevention of acute myocardial infarction (SEPAT) – guidelines adherence and outcome
por: Ergatoudes, Constantinos, et al.
Publicado: (2016)

Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction
por: Halvorsen, Sigrun, et al.
Publicado: (2016)

Does uptake of specialty care affect HRQoL development in COPD patients beneficially? A difference-in-difference analysis linking claims and survey data
por: Stöber, Alisa, et al.
Publicado: (2023)

The Effect of BMI and Type 2 Diabetes on Socioeconomic Status: A Two-Sample Multivariable Mendelian Randomization Study
por: Pedron, Sara, et al.
Publicado: (2021)

Cost‐effectiveness of an adherence‐enhancing intervention for gout based on real‐world data
por: Lin, Lydia Wenxin, et al.
Publicado: (2018)

Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data
por: Stöber, Alisa, et al.
Publicado: (2021)

Diverging Trends in Age at First Myocardial Infarction: Evidence from Two German Population-Based Studies
por: Beller, Johannes, et al.
Publicado: (2020)

Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand
por: Trerayapiwat, Krittimeth, et al.
Publicado: (2022)

Pharmacologic treatment of depression in patients with myocardial infarction
por: Ha, Jeong-Hoon, et al.
Publicado: (2011)

Costs and benefits of treatment of myocardial infarction
por: Simoons, M. L.
Publicado: (2013)

Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy
por: Degli Esposti, Luca, et al.
Publicado: (2022)

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
por: Moccia, Marcello, et al.
Publicado: (2022)

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
por: Liang, Zhe, et al.
Publicado: (2021)

Self‐Controlled Case‐Series Study to Verify the Effect of Adherence to Beta‐Blockers in Secondary Prevention of Myocardial Infarction
por: Di Bartolomeo, Stefano, et al.
Publicado: (2015)

Association of Diabetes Mellitus Status and Glycemic Control With Secondary Prevention Medication Adherence After Acute Myocardial Infarction
por: Adamek, Kylie E., et al.
Publicado: (2019)

Risk of Parkinson Disease and Secondary Parkinsonism in Myocardial Infarction Survivors
por: Sundbøll, Jens, et al.
Publicado: (2022)

Pharmacological Modulation of Cardiac Remodeling after Myocardial Infarction
por: Zhao, Wei, et al.
Publicado: (2020)

Cost-effectiveness of percutaneous coronary intervention versus medical therapy in patients with acute myocardial infarction: real-world and lifetime-horizon data from Taiwan
por: Liao, Chia-Te, et al.
Publicado: (2021)

Repetitive Myocardial Infarctions Secondary to Delirium Tremens
por: Schwartzberg, David, et al.
Publicado: (2014)

Acute Myocardial Infarction Secondary to Paradoxical Embolism
por: Alenezi, Abdullah R, et al.
Publicado: (2020)

Adherence to treatment assessed with the Adherence in Chronic Diseases Scale in patients after myocardial infarction
por: Kosobucka, Agata, et al.
Publicado: (2018)

Cost-Effectiveness and Cost–Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran
por: Amirsadri, Mohammadreza, et al.
Publicado: (2021)

Routine Use of the “Penumbra” Thrombectomy Device in Myocardial Infarction: A Real-World Experience—ROPUST Study
por: Tashtish, Nour, et al.
Publicado: (2022)

Diagnosing Medication Non-Adherence in a Patient with Myocardial Infarction
por: Ye, Siqin, et al.
Publicado: (2012)

Medication adherence and its determinants in patients after myocardial infarction
por: Pietrzykowski, Łukasz, et al.
Publicado: (2020)

Prescribing and medical non-adherence after myocardial infarction: qualitative interviews with general practitioners in Germany
por: Freier, Christian, et al.
Publicado: (2020)

Adherence to omalizumab: A multicenter "real-world" study
por: Campisi, Raffaele, et al.
Publicado: (2020)

Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy
por: Tsioufis, Konstantinos, et al.
Publicado: (2021)

The impact of time-window bias on the assessment of the long-term effect of medication adherence: the case of secondary prevention after myocardial infarction
por: Di Martino, Mirko, et al.
Publicado: (2015)

Network Pharmacology Analyses of the Pharmacological Targets and Therapeutic Mechanisms of Salvianolic Acid A in Myocardial Infarction
por: Huang, Qing, et al.
Publicado: (2022)

Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
por: Bally, Michèle, et al.
Publicado: (2017)

The role of late reperfusion in ST-segment elevation myocardial infarction: a real-world retrospective cohort study
por: Guo, Qixin, et al.
Publicado: (2020)

Chronic kidney disease and the outcomes of fibrinolysis for ST-segment elevation myocardial infarction: A real-world study
por: Xie, Wuxiang, et al.
Publicado: (2021)

Association between Cystatin C and Cardiac Function in Acute Myocardial Infarction Patients: A Real-World Analysis
por: Lou, Bowen, et al.
Publicado: (2022)

Impact of Patient Selection on Performance of an Early Rule-Out Pathway for Myocardial Infarction: From Research to the Real World
por: Bularga, Anda, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9halp0nh2f0ulkgkchj68vg1si